Regulatory Guidance Monthly Review - February 2024
Stay up-to-date with the latest regulatory guidance updates from the FDA in February 2024. From clinical trial regulations to drug approvals, this...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.

Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry (published 01-Apr-2024)
Download FDA Guidance
Study Data Technical Conformance Guide - Technical Specifications Document (published 01-Apr-2024)
Download FDA Guidance
Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry (published 01-Apr-2024)
Download FDA Guidance
Data Standards Catalog (published 16-Apr-2024)
Download FDA Guidance
Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels (published 30-Apr-2024)
Download FDA Guidance
Data Integrity for In Vivo Bioavailability and Bioequivalence Studies (published 03-Apr-2024)
Draft FDA Guidance
Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry (published 24-Apr-2024)
Draft FDA Guidance
Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications (published 25-Apr-2024)
Draft FDA Guidance
Cancer Clinical Trial Eligibility Criteria: Performance Status (published 25-Apr-2024)
Draft FDA Guidance
Approval Date: 04/03/2024
Drug Name: ZEVTERANDA #218275
Active Ingredients: CEFTOBIPROLE MEDOCARIL SODIUM
Submission Classification*: Type 1 - New Molecular Entity
Review Priority**: Priority
Company: BASILEA PHARM ALLSCH
Approval Date: 04/04/2024
Drug Name: XROMINDA #216593
Active Ingredients: HYDROXYUREA
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Priority
Company: NOVA LABS LTD
Approval Date: 04/10/2024
Drug Name: RETEVMONDA #218160
Active Ingredients: SELPERCATINIB
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: LOXO ONCOL ELI LILLY
Approval Date: 04/12/2024
Drug Name: ENTRESTONDA #218591
Active Ingredients: SACUBITRIL;VALSARTAN
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: NOVARTIS
Approval Date: 04/12/2024
Drug Name: ENTRESTO SPRINKLENDA #218591
Active Ingredients: SACUBITRIL; VALSARTAN
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: NOVARTIS
Approval Date: 04/12/2024
Drug Name: ENTRESTO SPRINKLENDA #218591
Active Ingredients: SACUBITRIL;VALSARTAN
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: NOVARTIS
Approval Date: 04/16/2024
Drug Name: SELARSDIBLA #761343
Active Ingredients: USTEKINUMAB-AEKN
Submission Classification*:
Review Priority**:
Company: ALVOTECH USA INC
Approval Date: 04/17/2024
Drug Name: LUMISIGHTNDA #214511
Active Ingredients: PEGULICIANINE
Submission Classification*: Type 1 - New Molecular Entity
Review Priority**: Priority
Company: LUMICELL
Approval Date: 04/17/2024
Drug Name: LUMISIGHTNDA #214511
Active Ingredients: PEGULICIANINE ACETATE
Submission Classification*: Type 1 - New Molecular Entity
Review Priority**: Priority
Company: LUMICELL
Approval Date: 04/18/2024
Drug Name: ENTYVIOBLA #761359
Active Ingredients: VEDOLIZUMAB
Submission Classification*:
Review Priority**:
Company: TAKEDA PHARMS USA
Approval Date: 04/19/2024
Drug Name: REZENOPYNDA #215487
Active Ingredients: NALOXONE HYDROCHLORIDE
Submission Classification*: Type 5 - New Formulation or New Manufacturer
Review Priority**: Standard
Company: SUMMIT BIOSCI
Approval Date: 04/19/2024
Drug Name: LUMIFY PRESERVATIVE FREENDA #218424
Active Ingredients: BRIMONIDINE TARTRATE
Submission Classification*: Type 5 - New Formulation or New Manufacturer
Review Priority**: Standard
Company: BAUSCH AND LOMB INC
Approval Date: 04/22/2024
Drug Name: ANKTIVABLA #761336
Active Ingredients: nogapendekin alfa inbakicept-pmln
Submission Classification*:
Review Priority**:
Company: ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU
Approval Date: 04/23/2024
Drug Name: OJEMDANDA #217700
Active Ingredients: TOVORAFENIB
Submission Classification*: Type 1 - New Molecular Entity
Review Priority**: Priority
Company: DAY ONE BIOPHARMACEUTICALS INC
Approval Date: 04/23/2024
Drug Name: OJEMDANDA #218033
Active Ingredients: TOVORAFENIB
Submission Classification*: Type 1 - New Molecular Entity
Review Priority**: Priority
Company: DAY ONE BIOPHARMACEUTICALS INC
Approval Date: 04/24/2024
Drug Name: PIVYANDA #216483
Active Ingredients: AMDINOCILLIN PIVOXIL
Submission Classification*: Type 2 - New Active Ingredient
Review Priority**: Priority
Company: UTILITY THERAPEUTICS LTD
Approval Date: 04/24/2024
Drug Name: VIJOICENDA #218466
Active Ingredients: ALPELISIB
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: NOVARTIS PHARMS CORP
Approval Date: 04/25/2024
Drug Name: HERCESSIBLA #761346
Active Ingredients: TRASTUZUMAB-STRF
Submission Classification*:
Review Priority**:
Company: ACCORD BIOPHARMA INC.
Approval Date: 04/26/2024
Drug Name: RINVOQNDA #218347
Active Ingredients: UPADACITINIB
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: ABBVIE INC
Approval Date: 04/26/2024
Drug Name: RINVOQ LQNDA #218347
Active Ingredients: UPADACITINIB
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: ABBVIE INC
Approval Date: 04/26/2024
Drug Name: LIBERVANTNDA #218623
Active Ingredients: DIAZEPAM
Submission Classification*: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Review Priority**: Standard
Company: AQUESTIVE THERAPEUTICS INC
Approval Date: 04/26/2024
Drug Name: XOLREMDINDA #218709
Active Ingredients: MAVORIXAFOR
Submission Classification*: Type 1 - New Molecular Entity
Review Priority**: Priority
Company: X4 PHARMACEUTICALS INC
Approval Date: 04/30/2024
Drug Name: VASOPRESSINNDA #217766
Active Ingredients: VASOPRESSIN
Submission Classification*: Type 3 - New Dosage Form
Review Priority**: Standard
Company: LONG GROVE PHARMS
Approval Date: 04/30/2024
Drug Name: INGREZZA SPRINKLENDA #218390
Active Ingredients: VALBENAZINE
Submission Classification*:
Review Priority**: Standard
Company: NEUROCRINE
05/09/2024- Blood Products Advisory Committee Meeting- 9:30 AM EDT to 3:10 PM EDT
05/16/2024- Vaccines and Related Biological Products Advisory Committee Meeting- 8:30 AM EDT to 4:30 PM EDT
05/22/2024- Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting- 10:00 AM EDT to 3:45 PM EDT
05/24/2024- Endocrinologic and Metabolic Drugs Advisory Committee Meeting- 9:00 AM EDT to 4:00 PM EDT

Industry wants to avoid surprises in remote regulatory assessments (published 01-Apr-2024)
Read Article on RAPS.org
FDA reprimands test makers over improper severity ratings, marketing unauthorized diagnostic (published 03-Apr-2024)
Read Article on RAPS.org
Study: Few FDA-approved targeted cancer drugs meet ESMO benefit benchmarks (published 04-Apr-2024)
Read Article on RAPS.org
FDA biostatistician recommends transparency, early conversation with reviewers (published 04-Apr-2024)
Read Article on RAPS.org
EMA says it will consider conditional approval for NASH drugs using intermediate endpoints (published 05-Apr-2024)
Read Article on RAPS.org
Study: Accelerated approvals leave lingering uncertainty about cancer drugs’ benefits (published 08-Apr-2024)
Read Article on RAPS.org
FDA statistician offers tips for evaluating wearables for clinical trials (published 09-Apr-2024)
Read Article on RAPS.org
Drug shortages: Study examines pandemic supply chain, HHS proposes resilience incentive (published 09-Apr-2024)
Read Article on RAPS.org
European Parliament adopts pharmaceutical reform package (published 11-Apr-2024)
Read Article on RAPS.org
FDA launches new clinical trial center to improve innovation, communication (published 15-Apr-2024)
Read Article on RAPS.org
FDA officials say FY 2025 budget increase needed to offset inflationary pay increases (published 16-Apr-2024)
Read Article on RAPS.org
ICH M13A BE testing guideline expected to be adopted this summer (published 17-Apr-2024)
Read Article on RAPS.org
Regulators explain process for requesting real-world evidence studies by EMA (published 18-Apr-2024)
Read Article on RAPS.org
WHO issues guidance on nitrosamine controls in drug manufacturing (published 19-Apr-2024)
Read Article on RAPS.org
Study: Many non-oncologic surrogate markers lack meta-analyses linking them to outcomes (published 22-Apr-2024)
Read Article on RAPS.org
Industry advises practical fixes for new FDA guidance on data monitoring committees (published 23-Apr-2024)
Read Article on RAPS.org
EMA group calls for multi-prong measures to tackle shortages (published 23-Apr-2024)
Read Article on RAPS.org
CBER chief on remote work, CRISPR-Cas9, and rare disease gene therapy accelerated approval guidance (published 24-Apr-2024)
Read Article on RAPS.org
FDA provides update on status of postmarketing reports and commitments (published 25-Apr-2024)
Read Article on RAPS.org
FDA updates guidance on promotional labeling and advertising of biosimilars (published 26-Apr-2024)
Read Article on RAPS.org
FDA issues three guidances to expand cancer clinical trial eligibility (published 29-Apr-2024)
Read Article on RAPS.org
FDA drafts two guidances on safety testing for cell and gene therapy products
Read Article on RAPS.org

Stay up-to-date with the latest regulatory guidance updates from the FDA in February 2024. From clinical trial regulations to drug approvals, this...
Stay up-to-date with the latest regulatory guidance updates from the FDA in December 2023. From clinical trial regulations to drug approvals, this...
Stay up-to-date with the latest regulatory guidance updates from the FDA in October 2023. From clinical trial regulations to drug approvals, this...